|
CN109554350B
(zh)
|
2012-11-27 |
2022-09-23 |
儿童医疗中心有限公司 |
用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件
|
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
|
CA2946312A1
(en)
|
2014-04-23 |
2015-10-29 |
Juno Therapeutics, Inc. |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
|
HUE049514T2
(hu)
|
2014-04-25 |
2020-09-28 |
Bluebird Bio Inc |
Javított eljárások adoptív sejtterápiák kialakítására
|
|
MX375592B
(es)
|
2014-04-25 |
2025-03-06 |
The Children´S Medical Center Corp |
Composiciones y su uso para tratar hemoglobinopatias.
|
|
PL3134432T3
(pl)
|
2014-04-25 |
2020-10-19 |
Bluebird Bio, Inc. |
Promotor mnd chimeryczne receptory antygenowe
|
|
SI3151672T1
(sl)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
ES2878449T3
(es)
|
2014-07-24 |
2021-11-18 |
2Seventy Bio Inc |
Receptores antigénicos quiméricos de BCMA
|
|
SI3226897T1
(sl)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
|
MY191537A
(en)
|
2014-12-05 |
2022-06-30 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
HRP20191873T1
(hr)
|
2014-12-12 |
2020-01-24 |
Bluebird Bio, Inc. |
Kimerni antigenski receptori
|
|
EP3234120B1
(en)
|
2014-12-15 |
2025-09-03 |
The Regents of the University of California |
Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
|
|
FI3240805T3
(fi)
|
2014-12-15 |
2025-02-17 |
Univ California |
Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
|
|
US10294304B2
(en)
|
2015-04-13 |
2019-05-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
US11572543B2
(en)
|
2015-05-08 |
2023-02-07 |
The Children's Medical Center. Corporation |
Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction
|
|
SI3331910T1
(sl)
|
2015-08-03 |
2020-07-31 |
Engmab Sarl |
Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
|
|
WO2018028647A1
(en)
|
2016-08-10 |
2018-02-15 |
Legend Biotech Usa Inc. |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
PL3368571T3
(pl)
|
2015-10-30 |
2023-05-02 |
The Regents Of The University Of California |
Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
ES2891578T3
(es)
|
2016-04-01 |
2022-01-28 |
Kite Pharma Inc |
Antígeno quimérico y receptores de células T y métodos de uso
|
|
TWI795133B
(zh)
|
2016-04-01 |
2023-03-01 |
美商凱特製藥公司 |
Ｂｃｍａ結合分子類及彼等之用途
|
|
CA3019650C
(en)
|
2016-04-01 |
2023-07-25 |
Kite Pharma, Inc. |
Chimeric receptors and methods of use thereof
|
|
US20190161530A1
(en)
*
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
|
KR20250175345A
(ko)
|
2016-06-21 |
2025-12-16 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
US20190233533A1
(en)
|
2016-06-28 |
2019-08-01 |
Umc Utrecht Holding B.V. |
Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
|
|
AU2017319702B2
(en)
|
2016-09-02 |
2024-11-14 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
|
PE20241349A1
(es)
|
2016-09-14 |
2024-07-03 |
Teneobio Inc |
Anticuerpos de union a cd3
|
|
WO2018085690A1
(en)
|
2016-11-04 |
2018-05-11 |
Bluebird Bio, Inc. |
Anti-bcma car t cell compositions
|
|
CA3043768A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
EP3548055A4
(en)
|
2016-12-02 |
2020-08-19 |
University of Southern California |
SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
|
|
IL317134A
(en)
*
|
2016-12-21 |
2025-01-01 |
Teneobio Inc |
An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
|
|
CN108276493B
(zh)
*
|
2016-12-30 |
2023-11-14 |
南京传奇生物科技有限公司 |
一种嵌合抗原受体及其应用
|
|
WO2018133877A1
(zh)
*
|
2017-01-23 |
2018-07-26 |
科济生物医药（上海）有限公司 |
靶向bcma的抗体及其应用
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
MX2019009552A
(es)
|
2017-02-17 |
2019-10-02 |
Hutchinson Fred Cancer Res |
Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
|
|
JP7228523B2
(ja)
*
|
2017-03-29 |
2023-02-24 |
ブルーバード バイオ， インコーポレイテッド |
ヘモグロビン異常症を治療するためのベクターおよび組成物
|
|
US11261441B2
(en)
|
2017-03-29 |
2022-03-01 |
Bluebird Bio, Inc. |
Vectors and compositions for treating hemoglobinopathies
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CN118948892A
(zh)
|
2017-05-01 |
2024-11-15 |
朱诺治疗学股份有限公司 |
细胞疗法与免疫调节化合物的组合
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
US11788087B2
(en)
|
2017-05-25 |
2023-10-17 |
The Children's Medical Center Corporation |
BCL11A guide delivery
|
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CN110945026B
(zh)
|
2017-06-20 |
2024-03-19 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
CN107475194B
(zh)
*
|
2017-10-09 |
2018-07-24 |
天津长和生物技术有限公司 |
Nkt细胞培养基、培养方法及二者的应用
|
|
AU2018351050B2
(en)
|
2017-10-18 |
2025-09-18 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
PT3703750T
(pt)
*
|
2017-11-01 |
2025-01-17 |
Memorial Sloan Kettering Cancer Center |
Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
|
|
SG11202003501XA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
MX2020004568A
(es)
|
2017-11-06 |
2020-10-05 |
Juno Therapeutics Inc |
Combinación de una terapia celular y un inhibidor de gamma secretasa.
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
CN111787938A
(zh)
|
2017-11-15 |
2020-10-16 |
诺华股份有限公司 |
靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
|
|
JP7517983B2
(ja)
*
|
2017-11-20 |
2024-07-17 |
ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク |
非常に低レベルのｃｄ１９を発現する骨髄腫細胞を除去するｃｄ１９ｃａｒｔ細胞
|
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
CN109971715A
(zh)
*
|
2017-12-28 |
2019-07-05 |
深圳华大生命科学研究院 |
一种扩增特异性car-t细胞的培养方法
|
|
US12539308B2
(en)
|
2018-01-08 |
2026-02-03 |
The Trustees Of The University Of Pennsylvania |
Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3674327A4
(en)
*
|
2018-02-01 |
2021-05-05 |
Nanjing Iaso Biotherapeutics Co., Ltd. |
BINDING OF CHIMERIC ANTIGEN RECEPTOR (CAR) TO BCMA AND USES THEREOF
|
|
PT3674328T
(pt)
*
|
2018-02-01 |
2024-03-14 |
Innovent Biologics Suzhou Co Ltd |
Recetor de antigénio quimérico (car) que se liga a bcma e utilizações do mesmo
|
|
CN110157675B
(zh)
*
|
2018-02-12 |
2022-05-27 |
深圳宾德生物技术有限公司 |
一种靶向性t淋巴细胞及其制备方法和应用
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
BR112020017053A2
(pt)
|
2018-02-21 |
2020-12-15 |
Celgene Corporation |
Anticorpos que se ligam ao bcma e usos dos mesmos
|
|
CA3089230A1
(en)
|
2018-03-02 |
2019-09-06 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
EP3549597A1
(en)
*
|
2018-04-06 |
2019-10-09 |
Heinrich-Heine-Universität Düsseldorf |
Synthetic signalling constructs and its use
|
|
CN116836297A
(zh)
*
|
2018-04-12 |
2023-10-03 |
上海赛比曼生物科技有限公司 |
靶向bcma的嵌合抗原受体及其制法和应用
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
WO2019213273A1
(en)
|
2018-05-01 |
2019-11-07 |
The Children's Medical Center Corporation |
Enhanced bcl11a rnp / crispr delivery & editing using a 3xnls-cas9
|
|
WO2019213013A1
(en)
|
2018-05-02 |
2019-11-07 |
The Children's Medical Center Corporation |
Improved bcl11a micrornas for treating hemoglobinopathies
|
|
MX2020012028A
(es)
|
2018-05-11 |
2021-03-29 |
Crispr Therapeutics Ag |
Metodos y composiciones para tratar el cancer.
|
|
KR102870868B1
(ko)
|
2018-06-01 |
2025-10-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
CN112566643A
(zh)
*
|
2018-06-12 |
2021-03-26 |
加利福尼亚大学董事会 |
用于治疗癌症的单链双特异性嵌合抗原受体
|
|
TWI890660B
(zh)
*
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
JP7357012B2
(ja)
*
|
2018-06-14 |
2023-10-05 |
２セブンティ バイオ インコーポレイテッド |
抗ｂｃｍａ ｃａｒ抗体、コンジュゲート、および使用方法
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
SG11202008731XA
(en)
*
|
2018-06-19 |
2020-10-29 |
Nanjing Legend Biotech Co Ltd |
Engineered cells and uses thereof
|
|
TW202019474A
(zh)
*
|
2018-07-11 |
2020-06-01 |
美商西建公司 |
抗bcma嵌合抗原受體之用途
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
MD3823665T2
(ro)
*
|
2018-07-19 |
2024-05-31 |
Regeneron Pharma |
Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
US12516099B2
(en)
|
2018-08-09 |
2026-01-06 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
|
AU2019317229A1
(en)
|
2018-08-10 |
2021-02-18 |
Eutilex Co.,Ltd |
Chimeric Antigen Receptor that Binds HLA-DR, and CAR-T Cell
|
|
CN109134665B
(zh)
*
|
2018-08-24 |
2021-06-11 |
上海先博生物科技有限公司 |
一种基于单域抗体的bcma嵌合抗原受体及应用
|
|
EP3845244A4
(en)
|
2018-08-24 |
2022-09-07 |
Shenzhen Pregene Biopharma Co. Ltd. |
ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND THEIR USE
|
|
EP4635978A2
(en)
|
2018-08-31 |
2025-10-22 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3847254A4
(en)
|
2018-09-07 |
2022-08-10 |
Beam Therapeutics Inc. |
COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM
|
|
WO2020051562A2
(en)
|
2018-09-07 |
2020-03-12 |
Beam Therapeutics Inc. |
Compositions and methods for improving base editing
|
|
IL281428B2
(en)
|
2018-09-27 |
2024-10-01 |
Autolus Ltd |
Chimeric antigen receptor
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
MA54078A
(fr)
*
|
2018-11-01 |
2021-09-15 |
Juno Therapeutics Inc |
Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
EP3873937A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
|
CA3117978A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
|
KR20210111244A
(ko)
*
|
2018-11-30 |
2021-09-10 |
셀룰래리티 인코포레이티드 |
태반-유래 동종이계 car-t 세포 및 이의 용도
|
|
MX2021006399A
(es)
*
|
2018-11-30 |
2021-07-15 |
Windmil Therapeutics Inc |
Linfocitos infiltrantes de medula osea (mils) que expresan receptores de antigenos quimericos (car), metodo de fabricacion de los mismos y metodo de uso en terapia.
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109651511B
(zh)
*
|
2018-12-26 |
2020-06-09 |
广州百暨基因科技有限公司 |
一种靶向bcma的嵌合抗原受体及其应用
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
US20230192805A1
(en)
*
|
2019-01-14 |
2023-06-22 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric receptor polypeptides and uses thereof
|
|
CN111454358A
(zh)
*
|
2019-01-18 |
2020-07-28 |
四川科伦博泰生物医药股份有限公司 |
一种嵌合抗原受体及其应用
|
|
AU2020215730A1
(en)
|
2019-01-31 |
2021-07-29 |
Beam Therapeutics Inc. |
Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors
|
|
CN120174005A
(zh)
|
2019-02-13 |
2025-06-20 |
比姆医疗股份有限公司 |
具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
CA3199205A1
(en)
|
2019-03-15 |
2020-09-24 |
Cartesian Therapeutics, Inc. |
Anti-bcma chimeric antigen receptors
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
CA3132587A1
(en)
|
2019-03-21 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
WO2020206330A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
JP7584437B2
(ja)
*
|
2019-04-05 |
2024-11-15 |
２セブンティ バイオ インコーポレイテッド |
抗ｂｃｍａ ｃａｒ ｔ細胞の製造
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
MX2021013359A
(es)
|
2019-04-30 |
2022-01-31 |
Crispr Therapeutics Ag |
Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
JP7489407B2
(ja)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
CN111850013B
(zh)
*
|
2019-06-25 |
2021-05-18 |
浙江康佰裕生物科技有限公司 |
一种共刺激受体增效的嵌合抗原受体及其应用
|
|
CN112143700B
(zh)
*
|
2019-06-26 |
2024-07-19 |
上海细胞治疗集团股份有限公司 |
制备过表达外源基因的免疫效应细胞的方法
|
|
JP7557522B2
(ja)
|
2019-07-16 |
2024-09-27 |
オリック ファーマシューティカルズ，インク． |
Ｃｄ７３阻害剤
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
EP4013883A1
(en)
|
2019-08-16 |
2022-06-22 |
Janssen Biotech, Inc. |
Therapeutic immune cells with improved function and methods for making the same
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
EP4031577A4
(en)
*
|
2019-09-18 |
2023-12-20 |
Board of Regents, The University of Texas System |
METHOD FOR ENGINEERING NATURAL KILLER CELLS TO TARGET BCMA-POSITIVE TUMORS
|
|
EP4032907A4
(en)
*
|
2019-09-20 |
2023-07-05 |
Shanghai Genbase Biotechnology Co., Ltd. |
Bcma-targeted antibody and chimeric antigen receptor
|
|
MX2022003414A
(es)
*
|
2019-09-25 |
2022-04-18 |
Fate Therapeutics Inc |
Celulas efectoras con multiples objetivos y uso de las mismas.
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
PL4051688T3
(pl)
*
|
2019-10-30 |
2025-09-22 |
Oric Pharmaceuticals, Inc. |
Inhibitory cd73
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
WO2021091978A1
(en)
|
2019-11-05 |
2021-05-14 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
CN112980886B
(zh)
*
|
2019-12-02 |
2022-02-22 |
河北森朗生物科技有限公司 |
一种能高效制备且应用安全的嵌合抗原受体t细胞及其制备方法与应用
|
|
IL293462A
(en)
*
|
2019-12-04 |
2022-07-01 |
Celularity Inc |
Placenta-derived allogeneic car-t cells and uses thereof
|
|
WO2021121228A1
(en)
*
|
2019-12-16 |
2021-06-24 |
Nanjing Legend Biotech Co., Ltd. |
Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
|
|
CN114929277A
(zh)
*
|
2019-12-16 |
2022-08-19 |
2赛文缇生物公司 |
抗bcma car抗体、缀合物及使用方法
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
IL295381B1
(en)
*
|
2020-02-12 |
2026-04-01 |
Juno Therapeutics Inc |
BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
|
|
JP7439279B2
(ja)
|
2020-02-13 |
2024-02-27 |
イミュノファーム テクノロジー カンパニー リミテッド |
キメラ抗原受容体の最適化
|
|
MX2022009827A
(es)
*
|
2020-02-14 |
2022-09-05 |
Univ Leland Stanford Junior |
Receptores de antigenos quimericos con activacion de cd2.
|
|
EP4110376A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
JP2023522857A
(ja)
|
2020-04-10 |
2023-06-01 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
|
|
US12264190B2
(en)
*
|
2020-04-24 |
2025-04-01 |
Astrazeneca Ab |
Compositions and methods of treating cancer with chimeric antigen receptors
|
|
US20230165872A1
(en)
|
2020-04-28 |
2023-06-01 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
KR20230010231A
(ko)
*
|
2020-05-11 |
2023-01-18 |
아빈투스 바이오, 인코포레이티드 |
생체내 형질도입을 위한 벡터 및 방법
|
|
JP2023529211A
(ja)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
Ｚｂｔｂ３２阻害剤及びその使用
|
|
US20220033383A1
(en)
|
2020-07-20 |
2022-02-03 |
Enanta Pharmaceuticals, Inc. |
Functionalized peptides as antiviral agents
|
|
CN111909271B
(zh)
*
|
2020-08-12 |
2021-03-23 |
深圳市茵冠生物科技有限公司 |
一种基于单域抗体的bcma嵌合抗原受体及其应用
|
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
|
CN111944850B
(zh)
*
|
2020-08-28 |
2023-03-31 |
澳门大学 |
表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用
|
|
CA3196831A1
(en)
|
2020-09-25 |
2022-03-31 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
US12540141B2
(en)
|
2020-11-23 |
2026-02-03 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
|
KR20230124583A
(ko)
|
2020-11-23 |
2023-08-25 |
이난타 파마슈티칼스, 인코포레이티드 |
신규한 스피로피롤리딘 유래 항바이러스제
|
|
US11384090B2
(en)
|
2020-11-23 |
2022-07-12 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
|
US11352363B1
(en)
|
2020-11-23 |
2022-06-07 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
|
EP4272002A1
(en)
|
2020-12-04 |
2023-11-08 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
CN117693508A
(zh)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
T细胞疗法和dgk抑制剂的组合
|
|
US20260055430A1
(en)
*
|
2021-03-08 |
2026-02-26 |
Flagship Pioneering Innovations Vi, Llc |
Lentivirus with altered integrase activity
|
|
CN118201618A
(zh)
|
2021-04-16 |
2024-06-14 |
细胞基因公司 |
与bcma定向t细胞疗法的组合疗法
|
|
JP2024517413A
(ja)
|
2021-04-16 |
2024-04-22 |
セルジーン コーポレーション |
以前に幹細胞移植を受けた患者におけるｔ細胞療法
|
|
WO2022229853A1
(en)
|
2021-04-27 |
2022-11-03 |
Novartis Ag |
Viral vector production system
|
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
|
US11319325B1
(en)
|
2021-05-11 |
2022-05-03 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic spiropyrrolidine derived antiviral agents
|
|
EP4347859A4
(en)
*
|
2021-05-26 |
2025-07-02 |
Flagship Pioneering Innovations Vi Llc |
INTEGRASE COMPOSITIONS AND METHODS
|
|
JP2024525727A
(ja)
|
2021-07-14 |
2024-07-12 |
２セブンティ バイオ インコーポレイテッド |
抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
|
|
US11325916B1
(en)
|
2021-07-29 |
2022-05-10 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
|
US11339170B1
(en)
|
2021-07-23 |
2022-05-24 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
|
EP4388000A1
(en)
|
2021-08-20 |
2024-06-26 |
Novartis AG |
Methods of making chimeric antigen receptor?expressing cells
|
|
AU2022380155A1
(en)
|
2021-11-03 |
2024-06-20 |
Janssen Biotech, Inc. |
Corticosteriod reduction in treatment with anti-cd38 antibodies
|
|
KR20240112994A
(ko)
|
2021-11-03 |
2024-07-19 |
셀진 코포레이션 |
골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
|
|
WO2023081750A1
(en)
*
|
2021-11-04 |
2023-05-11 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating metachromatic leukodystrophy disease and related disorders
|
|
KR20240137075A
(ko)
|
2022-01-28 |
2024-09-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 조성물의 제조 방법
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
US20250295771A1
(en)
|
2022-05-11 |
2025-09-25 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
JP2025520227A
(ja)
|
2022-05-26 |
2025-07-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
レンチウイルスベクターを維持するための組成物及びその使用
|
|
JP2025525937A
(ja)
|
2022-08-05 |
2025-08-07 |
ジュノー セラピューティクス インコーポレイテッド |
Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
|
|
EP4583876A1
(en)
|
2022-09-08 |
2025-07-16 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
WO2024124132A1
(en)
|
2022-12-09 |
2024-06-13 |
Juno Therapeutics, Inc. |
Machine learning methods for predicting cell phenotype using holographic imaging
|
|
KR20240094169A
(ko)
*
|
2022-12-13 |
2024-06-25 |
진셀비티 주식회사 |
B-세포 성숙 항원을 표적화하는 신규한 키메라 항원 수용체 및 이의 용도
|
|
JP2026504491A
(ja)
|
2023-02-03 |
2026-02-05 |
ツェー３エス２ ゲーエムベーハー |
操作された免疫細胞の非ウイルス的製造のための方法
|
|
WO2024168192A1
(en)
|
2023-02-10 |
2024-08-15 |
Celgene Corporation |
Assessment of bcma in biological samples
|
|
KR20250131823A
(ko)
|
2023-03-31 |
2025-09-03 |
아벨제타 인크. |
Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
|
|
AU2024279278A1
(en)
|
2023-05-31 |
2025-12-18 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025109119A1
(en)
|
2023-11-22 |
2025-05-30 |
Priothera Sas |
Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025160324A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
US20250276092A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025196590A1
(en)
*
|
2024-03-16 |
2025-09-25 |
Indian Institute Of Technology Bombay |
Novel anti-bcma chimeric antigen receptor, its nucleic acid sequence, and its preparation
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
CN118325927A
(zh)
*
|
2024-06-13 |
2024-07-12 |
广州安捷生物医学技术有限公司 |
编码nk细胞衔接器和car的多核苷酸及包含其的修饰细胞
|
|
WO2026006767A1
(en)
|
2024-06-28 |
2026-01-02 |
Dispatch Biotherapeutics, Inc. |
Tethered il-9/il-9r and related engineered cells and methods
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|